You are here: Industry Insights > ALS

News List

Experimental motor neurone disease therapy shows promise europeanpharmaceuticalreview
July 15, 2020
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.
Experimental motor neurone disease therapy shows early promise pharmatimes
July 14, 2020
An experimental therapy developed to address the genetic cause of a Amyotrophic lateral sclerosis (ALS), rare form of motor neurone disease (MND) has shown encouraging results in early research supported by the NIHR.
Clinigen's ALS therapy bags US orphan status pharmatimes
July 14, 2020
ALS is a severe, neurodegenerative disease which affects motor neurons leading to progressive muscle weakness, paralysis and ultimately death within a median time of two to four years from disease onset.
Yumanity Therapeutics signs drug development deal with Merck pharmaceutical-technology
June 28, 2020
US-based Yumanity Therapeutics has signed a research collaboration and licence agreement with Merck (MSD) to develop new therapies for neurodegenerative diseases.
ALS global day emphasises need for a cure despite promising late-stage pipeline pharmaceutical-technology
June 23, 2020
The International Alliance of Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Associations recognises 21 June as the ALS Global Day.
ALS Awareness Project Led by an ALS Patient prnasia
December 25, 2019
The END ALS Association (Representative: Motoi Ito, Tokyo, Japan) announced the launch of their?Merry & Bright - EEG Illumination project.
Amylyx Pharmaceuticals announces AMX0035 demonstrated statistically significant treatment benefit in ALS in CENTAUR trial pharmaceutical-business-review
December 20, 2019
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases ...
MetP Pharma Receives US Patent for Drug Therapy of Demyelinating and Neuroinflammatory Diseases such as Multiple Sclerosis b3cnewswire
December 18, 2019
MetP? Pharma AG announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for ...
Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis En-CPhI.CN
October 15, 2019
Collaborative Medicinal Development, LLC) ("CMD"), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric diseases.
Kadimastem Announces Results of Cohort A of ALS Trial americanpharmaceuticalreview
September 26, 2019
Kadimastem announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).